Released Presentations

  • IP19 : STRUCTURAL IMPLEMENTATION OF PATIENT PREFERENCES IN HEALTH TECHNOLOGY ASSESSMENT: WILL WE EVER GET THERE? A QUESTION RAISED BY IMI PREFER

    Presentation

    David Mott
    Economist, Office of Health Economics, London, UK
    Dr. Marco Petschulies
    Scientific Advisor, Federal Joint Committee (G-BA), Berlin, Germany
    Eline van Overbeeke
    PhD researcher, University of Leuven, Leuven, Belgium
  • IP26 : WILL REGENERATIVE MEDICINES CHANGE THE WAY WE EVALUATE EVIDENCE, FUND INNOVATION, AND DETERMINE VALUE?

    Presentation

    Michael Epstein Epstein
    MS, Principal, Evidera, Webster, USA
  • Keynote : Address

    Presentation

    Mark McClellan, MD, PhD
    Robert J. Margolis Professor of Business, Medicine, and Policy, and Director , Margolis Center for Health Policy at Duke University,
  • P17 : NEUROLOGICAL DISORDERS STUDIES

    COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON'S DISEASE

    Elise Cabout
    Msc, Project Manager, REES France, Paris, France
  • P17 : NEUROLOGICAL DISORDERS STUDIES

    META-ANALYSIS OF REAL-WORLD ADHERENCE AND PERSISTENCE OF MAINTENANCE ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS (DIMETHYL FUMARATE, FINGOLIMOD, AND TERIFLUNOMIDE) IN MULTIPLE SCLEROSIS

    Amy Phillips
    PharmD, Director, Health Economics & Outcomes Research, EMD Serono, Inc., Chattanooga, USA
  • P17 : NEUROLOGICAL DISORDERS STUDIES

    FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER’S

    Eddie Jones
    BA, Director – Neurology and Rare Diseases, Adelphi Real World, Manchester, United Kingdom
  • P17 : NEUROLOGICAL DISORDERS STUDIES

    AMBULATORY FUNCTION IN DUCHENNE MUSCULAR DYSTROPHY (DMD): THE CHARACTERISTIC TRAJECTORY AND VARIATION ACROSS INDIVIDUALS

    James Signorovitch
    PhD, Managing Principal, Analysis Group, Inc., Boston, USA
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Finn Børlum Kristensen, MD, PhD
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Roman Topór-Mądry
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Ansgar Hebborn, PhD
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Luciana Ballini
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Menno Aarnout
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Flora Giorgio
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?

    Presentation

    Félix Lobo, PhD
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?

    Presentation

    Peter C. Smith, MSc
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?

    Presentation

    Adrian Towse, MA, MPhil
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
  • W22 : POLICY MEASURES TO MAXIMISE PATIENT ACCESS AFTER THE INTRODUCTION OF BIOSIMILAR MEDICINES IN THE OFF-PATENT BIOLOGICAL MARKET

    Presentation

    Evelien Moorkens
    MSc, PhD Researcher, KU Leuven, Leuven, Belgium
  • W22 : POLICY MEASURES TO MAXIMISE PATIENT ACCESS AFTER THE INTRODUCTION OF BIOSIMILAR MEDICINES IN THE OFF-PATENT BIOLOGICAL MARKET

    Presentation

    Andras Inotai
    PharmD, PhD, DrHabil, Principal Researcher; Assistant Professor, 1) Syreon Research Institute 2) Eötvös Loránd University (ELTE), Budapest, Hungary